Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether the ingestion of the common food additive carrageenan contributes to insulin resistance and thus to the pathogenesis of type 2 diabetes in humans.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A | Other |
|
|
| Group B | Other |
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Carrageenan | Dietary Supplement | Carrageenan 250 mg bid supplemented to a standard food |
|
| Measure | Description | Time Frame |
|---|---|---|
| Insulin sensitivity assessed by oral glucose tolerance test (OGTT): Matsuda index | 2 weeks | |
| Insulin sensitivity assessed by hyperinsulinemic clamp: M-value | 2 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Endogenous glucose production measured by tracer-method | 2 weeks | |
| Cerebral insulin sensitivity measured by MRI | 2 weeks | |
| Intrahepatic triglyceride content |
| Measure | Description | Time Frame |
|---|---|---|
| Intestinal permeability | 2 weeks | |
| Intestinal microbiome constitution | 2 weeks | |
| Markers of systemic inflammation including lymphocyte activation, cytokines and adipokines |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Robert Wagner, M.D | University of Tübingen, Department of Internal Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Tübingen, Department of Internal Medicine | Tübingen | 72076 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39593091 | Derived | Wagner R, Buettner J, Heni M, Fritsche L, Kullmann S, Wagmuller M, Peter A, Preissl H, Machann J, Jumpertz von Schwartzenberg R, Birkenfeld AL, Pape UF, van Hall G, Plomgaard P, Haring HU, Fritsche A, Thompson KN, Klein R, Stefan N. Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial. BMC Med. 2024 Nov 26;22(1):558. doi: 10.1186/s12916-024-03771-8. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D002351 | Carrageenan |
| ID | Term |
|---|---|
| D011134 | Polysaccharides |
| D002241 | Carbohydrates |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Dietary Supplement | Placebo (Mannitol/Aerosil) bid supplemented to a standard food |
|
| 2 weeks |
| Glycemia during OGTT | 2 weeks |
| 2 weeks |
| D004700 | Endocrine System Diseases |
| D006946 | Hyperinsulinism |